OBJECTIVES: To improve the clinical outcome of patients with severe functional mitral regurgitation (FMR) associated with ischemic cardiomyopathy (ICM), we compared the therapeutic efficacy of mitral annuloplasty (MAP) with that of mitral valve replacement (MVR). METHODS: In a retrospective observation 63 consecutive patients underwent mitral valve surgery for severe ICM-FMR from November 1999 to March 2012. All patients had severe FMR (regurgitant volume >60 ml/beat) with Carpentier type I and type IIIb disease. Mean RV was 74.0 ± 35.0 ml/beat and coaptation depth was 12.7 ± 3.0 mm. Twenty-six patients (41.3 %) were treated by MVR with sparing of the subvalvular apparatus and 37 (58.7 %) by MAP. RESULTS: Total in-hospital mortality was 6.3 %. Kaplan-Meier survival estimates at 1 and 5 years were 84.2 and 78.6 % in the MVR group and 82.6 and 71.6 % in the MAP group, with no significant difference between groups (p = 0.758). Freedom from major adverse cardiac and cerebrovascular events (MACCE) at 5 years was 66.9 % for patients treated by MVR and 64.1 % for those treated by MAP (p = 0.866). At the last follow-up visit, >grade II MR had recurred in 4 annuloplasty patients (10.8 %). In multivariate analysis, independent predictors of increased late death and MACCE were significantly associated with residual pulmonary hypertension (late death: odds ratio = 25.0, p = 0.0009; MACCE: odds ratio = 31.3, p = 0.0001). CONCLUSIONS: Mitral valve replacement with sparing of the subvalvular apparatus is a safe and effective surgical alternative for patients with severe FMR.
OBJECTIVES: To improve the clinical outcome of patients with severe functional mitral regurgitation (FMR) associated with ischemic cardiomyopathy (ICM), we compared the therapeutic efficacy of mitral annuloplasty (MAP) with that of mitral valve replacement (MVR). METHODS: In a retrospective observation 63 consecutive patients underwent mitral valve surgery for severe ICM-FMR from November 1999 to March 2012. All patients had severe FMR (regurgitant volume >60 ml/beat) with Carpentier type I and type IIIb disease. Mean RV was 74.0 ± 35.0 ml/beat and coaptation depth was 12.7 ± 3.0 mm. Twenty-six patients (41.3 %) were treated by MVR with sparing of the subvalvular apparatus and 37 (58.7 %) by MAP. RESULTS: Total in-hospital mortality was 6.3 %. Kaplan-Meier survival estimates at 1 and 5 years were 84.2 and 78.6 % in the MVR group and 82.6 and 71.6 % in the MAP group, with no significant difference between groups (p = 0.758). Freedom from major adverse cardiac and cerebrovascular events (MACCE) at 5 years was 66.9 % for patients treated by MVR and 64.1 % for those treated by MAP (p = 0.866). At the last follow-up visit, >grade II MR had recurred in 4 annuloplasty patients (10.8 %). In multivariate analysis, independent predictors of increased late death and MACCE were significantly associated with residual pulmonary hypertension (late death: odds ratio = 25.0, p = 0.0009; MACCE: odds ratio = 31.3, p = 0.0001). CONCLUSIONS:Mitral valve replacement with sparing of the subvalvular apparatus is a safe and effective surgical alternative for patients with severe FMR.
Authors: Y Otsuji; M D Handschumacher; E Schwammenthal; L Jiang; J K Song; J L Guerrero; G J Vlahakes; R A Levine Journal: Circulation Date: 1997-09-16 Impact factor: 29.690
Authors: Vorachai Kongsaerepong; Maiko Shiota; A Marc Gillinov; Jong-Min Song; Shota Fukuda; Patrick M McCarthy; Timothy Williams; Robert Savage; Masao Daimon; James D Thomas; Takahiro Shiota Journal: Am J Cardiol Date: 2006-06-21 Impact factor: 2.778
Authors: E A Grossi; J D Goldberg; A LaPietra; X Ye; P Zakow; M Sussman; J Delianides; A T Culliford; R A Esposito; G H Ribakove; A C Galloway; S B Colvin Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: Edwin C McGee; A Marc Gillinov; Eugene H Blackstone; Jeevanantham Rajeswaran; Gideon Cohen; Farzad Najam; Takahiro Shiota; Joseph F Sabik; Bruce W Lytle; Patrick M McCarthy; Delos M Cosgrove Journal: J Thorac Cardiovasc Surg Date: 2004-12 Impact factor: 5.209
Authors: Antonio M Calafiore; Michele Di Mauro; Sabina Gallina; Gabriele Di Giammarco; Angela L Iacò; Giovanni Teodori; Isabella Tavarozzi Journal: Ann Thorac Surg Date: 2004-06 Impact factor: 4.330
Authors: Judy Hung; Lampros Papakostas; Stephen A Tahta; Bruce G Hardy; Bruce A Bollen; Carlos M Duran; Robert A Levine Journal: Circulation Date: 2004-09-14 Impact factor: 29.690
Authors: Sohaib A Virk; Arunan Sriravindrarajah; Douglas Dunn; Kevin Liou; Hugh Wolfenden; Genevieve Tan; Christopher Cao Journal: Ann Cardiothorac Surg Date: 2015-09
Authors: Daniel Goldstein; Alan J Moskowitz; Annetine C Gelijns; Gorav Ailawadi; Michael K Parides; Louis P Perrault; Judy W Hung; Pierre Voisine; Francois Dagenais; A Marc Gillinov; Vinod Thourani; Michael Argenziano; James S Gammie; Michael Mack; Philippe Demers; Pavan Atluri; Eric A Rose; Karen O'Sullivan; Deborah L Williams; Emilia Bagiella; Robert E Michler; Richard D Weisel; Marissa A Miller; Nancy L Geller; Wendy C Taddei-Peters; Peter K Smith; Ellen Moquete; Jessica R Overbey; Irving L Kron; Patrick T O'Gara; Michael A Acker Journal: N Engl J Med Date: 2015-11-09 Impact factor: 91.245